News >

FDA Approves Split-Dosing Regimen of Daratumumab for Multiple Myeloma

Gina Columbus @ginacolumbusonc
Published: Tuesday, Feb 12, 2019

The FDA has approved a split-dosing regimen of daratumumab (Darzalex) for patients with multiple myeloma, providing physicians the option to split the first infusion of the CD38-directed monoclonal antibody over 2 consecutive days or complete in a single session.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x